Restructurings & Charges

Compass, Inc. announced a restructuring with charges of approximately $10 million to $12 million.

“On January 5, 2023, Compass, Inc. (the “Company”) implemented a further workforce reduction (“Workforce Reduction”) as part of the Company’s ongoing cost reduction initiatives to manage the business during the current macroeconomic environment, as referenced in its third quarter earnings conference call on November 10, 2022. The Workforce Reduction is in addition to the strategic actions that were reported on the Company’s Form 8-Ks dated September 20, 2022 and June 14, 2022. The Company currently estimates that as a result of the Workforce Reduction, it will incur pre-tax cash charges of approximately $10 million to $12 million for severance and other termination benefits for employees whose roles were or are being eliminated during the quarter ending March 31, 2023.”

FATE THERAPEUTICS INC announced a restructuring with charges of approximately $15 million (approximately 220 employees).

“On January 5, 2023, the Company announced the prioritization of its current and near-term clinical programs and development plans, including advancement of a second-generation CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell program for hematologic malignancies and severe autoimmune disorders, its FT576 CAR NK cell program for multiple myeloma, its FT819 CAR T-cell program for B-cell lymphoma, and its FT825/ONO-8250 CAR T-cell program for solid tumors under its collaboration with ONO Pharmaceutical Co., Ltd.; and discontinuation of its FT516, FT596, FT538, and FT536 NK cell programs. The restructuring plan will result in a reduction in the Company’s workforce to approximately 220 employees, and is expected to be completed during the first quarter of 2023. These changes are expected to extend the Company’s cash runway through 2025. The Company estimates that it will incur charges of approximately $15 million for severance and other employee termination-related cost”

Silvergate Capital Corp announced a impairment with charges of $196 million impairment charge related to developed technology assets purchased in January 2022 affecting developed technology assets.

“After performing an impairment analysis of the Company’s intangible assets, the Company will take an impairment charge of $196 million in the fourth quarter of 2022 related to developed technology assets purchased in January 2022.”

Silvergate Capital Corp announced a restructuring with charges of $4.0 million restructuring charge incurred in the fourth quarter of 2022 primarily related to severance and employee benefit costs associated with the Company e affecting mortgage warehouse lending product exit.

“These costs are in addition to a $4.0 million restructuring charge incurred in the fourth quarter of 2022 primarily related to severance and employee benefit costs associated with the Company exiting its mortgage warehouse lending product in the fourth quarter of 2022.”

Silvergate Capital Corp announced a restructuring with charges of approximately $8.0 million, including approximately $6.1 million in severance payments and $1.3 million in employee benefits affecting employee headcount reduction of 200 employees (40% of workforce) (approximately 200 employees or 40% of its workforce).

“The Company is reducing its headcount by approximately 200 employees or 40% of its workforce in order to account for the economic realities facing the digital asset industry today. Reducing headcount will enable the Company to continue to offer a tailored customer experience, while prudently managing expenses in a more challenging macro environment. Impacted employees were notified on January 4, 2023, and the Company is providing these individuals with severance packages and job placement resources. The Company estimates aggregate costs associated with the reduction in force of approximately $8.0 million, including approximately $6.1 million in severance payments and $1.3 million in employee benefits.”

Y-mAbs Therapeutics, Inc. announced a restructuring with charges of approximately $5.0 million affecting its development and commercial organization (approximately 35%).

“As a result of the reduction in workforce and revised business plan, the Company expects to incur restructuring expenses of approximately $5.0 million, consisting predominantly of cash related notice and severance payments of approximately $3.0 million and acceleration of stock-based compensation of approximately $2.0 million.”

KALTURA INC announced a restructuring with charges of approximately $1 million (approximately 11% of the Company’s current workforce).

“On January 3, 2023, the Board of Directors of Kaltura, Inc. (the “Company”) approved a re-organization plan (the “Plan”) that includes, among other things, downsizing approximately 11% of the Company’s current workforce and adapting the Company's organizational structure, roles, and responsibilities accordingly. The total cost reduction from the downsizing on an annualized basis is expected to be approximately $16 million. The Plan is focused on realigning the Company’s operations to further increase efficiency and productivity, in reaction to the current macro-economic climate. The Plan's main objectives are to position the Company for lower demand, spend, and available budgets across the Company's market segments, align the Company's business strategy in light of these market conditions and support the Company’s growth initiatives and return path to profitability. In connection with the Plan, the Company expects to incur pre-tax charges of approximately $1 million, primarily for seve”

Salesforce, Inc. announced a restructuring with charges of The Company estimates that it will incur approximately $1.4 billion to $2.1 billion in charges in connection with the Plan, of which approximately $800 million affecting select real estate exits and office space reductions within certain markets (a reduction of the Company's current workforce by approximately 10 percent).

“are subject to local law and consultation requirements in certain countries, as well as the Company’s business needs. The Company estimates that it will incur approximately $1.4 billion to $2.1 billion in charges in connection with the Plan, of which approximately $800 million to $1.0 billion is expected to be incurred in the fourth quarter of fiscal 2023. These”

PEGASYSTEMS INC announced a restructuring with charges of $18.9 million (approximately 4% of its employees).

“Aligned with our target organization go-to-market strategy and commitment to be a Rule of 40 managed company, on January 3, 2023, Pegasystems Inc. (the “Company”) announced a reduction in its workforce of approximately 4% of its employees across various geographies. Communications to impacted persons or their representatives are expected to be completed in the first quarter 2023. The Company expects to incur a charge of $18.9 million in the fourth quarter of 2022 related principally to cash severance and related benefit costs for terminated employees.”

MASONITE INTERNATIONAL CORP announced a restructuring with charges of $15.0 to $20.0 million affecting North American Residential and Architectural segments.

“On December 27, 2022, Masonite International Corporation (the “Company”) approved a plan intended to (i) better align its organizational structure and its long-term business strategy and (ii) continue to drive cost efficiencies through an optimized manufacturing footprint. This plan includes commencing certain restructuring actions across the Company’s North American Residential and Architectural segments (the “2022 Restructuring Plan”). The Company expects to incur pre-tax restructuring and other closure costs of $15.0 to $20.0 million related to the 2022 Restructuring Plan beginning in the fourth quarter of 2022 and continuing through fiscal year 2023, of which approximately 65% will be cash expenditures.”

MOLINA HEALTHCARE, INC. announced a impairment with charges of approximately $200 million affecting leased space.

“On December 28, 2022, Molina Healthcare, Inc. (the “Company”) concluded that it will record in the fourth quarter of 2022 an estimated non-cash, pre-tax impairment charge of approximately $200 million, attributable to leased space.”

Akebia Therapeutics, Inc. announced a restructuring with charges of $32,500,000 affecting supply of ferric citrate drug substance for Auryxia.

“Under the terms of the Termination Agreement, the Company has agreed to pay to BioVectra a total of $32,500,000, consisting of (i) an upfront payment of $17,500,000 and (ii) six quarterly payments of $2,500,000 starting in April 2024, in consideration for the termination of the BioVectra Agreements”

FORRESTER RESEARCH, INC. announced a impairment with charges of in the range of $5 million to $6 million affecting 150 Spear Street, San Francisco, California.

“The Company anticipates incurring a non-cash asset impairment charge in the range of $5 million to $6 million in the fourth quarter of 2022 in connection with this reduction in space.”

ALLIED HEALTHCARE PRODUCTS INC announced a restructuring with charges of $17.5 million affecting St. Louis, Missouri manufacturing facilities and certain employees of its administrative offices.

“The reduction in force will result in the termination of substantially all of the Company’s union employees, which is expected to trigger withdrawal liabilities owed to certain multiemployer pension plans which were recently estimated by such pension plans to be $17.5 million.”

Inogen Inc announced a impairment with charges of loss on asset disposal of its technology intangible assets of approximately $53.4 million and loss on inventory of $0.2 to $0.3 million affecting technology intangible assets related to Tidal Assist Ventilator (TAV) technology acquired from New Aera.

“In connection with the Disposal Determination, the Company estimates it will incur a loss on asset disposal of its technology intangible assets of approximately $53.4 million and loss on inventory of $0.2 to $0.3 million, partially offset by a decrease in the fair value of the Company’s New Aera earnout liability of approximately $13.6 to $13.7 million.”

MICRON TECHNOLOGY INC announced a restructuring with charges of at least $30 million (approximately 10%).

“On December 21, 2022 , we announced a restructure plan in response to challenging industry conditions. Under the restructure plan, we expect to reduce our headcount by approximately 10% over calendar year 2023, through a combination of voluntary attrition and personnel reductions. In connection with the plan, we expect to incur charges of at least $30 million in the second quarter of fiscal 2023, substantially all in cash expenditures.”

TuSimple Holdings Inc. announced a restructuring with charges of approximately $10 million to $11 million affecting U.S. operations (approximately 350 employees, or 25% of the Company's global workforce).

“are expected to be approximately 1,100, including approximately 880 Research & Development FTEs. The Company currently estimates that it will incur charges of approximately $10 million to $11 million in connection with the Restructuring Plan, consisting primarily of cash expenditures for employee transition, notice period and severance payments, employee”

Insight Molecular Diagnostics Inc. announced a restructuring with charges of charges of over approximately $1.0 million related to employee severance and benefits costs affecting over 40% of its full-time employees (over 40% of its full-time employees).

“On December 16, 2022, Oncocyte announced a reduction in force involving over 40% of its full-time employees (the “Reduction”), which Oncocyte expects will decrease its annualized headcount carrying costs by over approximately $10 million, exclusive of related employee severance and benefit costs (as described further below). The Reduction began on December 16, 2022 and is expected to be completed in February 2023. In connection with the Reduction, we estimate that we will incur charges of over approximately $1.0 million related to employee severance and benefits costs.”

3M CO announced a impairment with charges of $0.7 billion to $1.0 billion affecting PFAS manufacturing.

“As a result of authorization by 3M Company’s Board of Directors on December 16, 2022 of the plan to exit per- and polyfluoroalkyl substance (PFAS) manufacturing by the end of 2025, 3M expects to incur an estimated pre-tax charge in a range of $0.7 billion to $1.0 billion in the fourth quarter of 2022, primarily non-cash and related to asset impairments. These impairments, in and of themselves, are not expected to result in material future cash expenditures.”

RingCentral, Inc. announced a impairment with charges of up to approximately $160 million affecting prepaid sales commission balance under its strategic partnership with Avaya Holdings Corp..

“reorganization, the Company expects to record a non-cash asset write-down charge of substantially all of the remaining prepaid sales commission balance of up to approximately $160 million in its financial results for the year ending December 31, 2022. In addition, the Company expects to take a write down of substantially all of the remaining fair value of the”

Trinseo PLC announced a restructuring with charges of $79 million to $89 million affecting Boehlen, Germany styrene plant; Stade, Germany polycarbonate line; Matamoros, Mexico PMMA sheet site; Hamina, Finland SB latex plant.

“The Company expects to incur total restructuring charges in connection with the Restructuring Plan ranging from approximately $79 million to $89 million.”

OTONOMY, INC. announced a restructuring with charges of aggregate charges of approximately $5.0 million for severance and other employee termination-related costs affecting all employees (termination of all employees).

“the Company has reduced its workforce, including the termination of all employees, effective as of December 15, 2022 (the “Reduction”). The Company estimates that it will incur aggregate charges of approximately $5.0 million for severance and other employee termination-related costs in the fourth quarter of 2022.”

LANNETT CO INC announced a impairment with charges of estimated range of $6 million to $8 million affecting Torresdale facility.

“the Company expects to record a non-cash impairment charge of its Torresdale facility in the estimated range of $6 million to $8 million in the second quarter of Fiscal 2023.”

LANNETT CO INC announced a restructuring with charges of approximately $3.0 million affecting State Road and Torresdale facilities in Philadelphia, Pennsylvania (by 64 positions, equal to approximately 11% of the Company's total number of employees).

“exiting our State Road and Torresdale facilities in Philadelphia, Pennsylvania by the end of our current fiscal year. The Company estimates that it will incur approximately $3.0 million in severance-related costs in connection with the 2022 Restructuring Plan, of which $0.4 million is expected to be incurred in the second quarter of Fiscal 2023. These expenses”

Axcella Health Inc. announced a restructuring with charges of up to $2.1 million (approximately 85% of the Company's workforce).

“As part of this restructuring, the Board approved a reduction in force of approximately 85% of the Company's workforce. Robert Crane, the Company's Chief Financial Officer and Virginia Dean, the Company's Senior Vice President, Chief People Officer were each part of the reduction in force. The reduction in force is a measure to manage costs and conserve cash resources with the goal of maximizing the opportunities available to Axcella during the Board's review of strategic alternatives to maximize shareholder value. The Company expects to record a charge of up to $2.1 million in the fourth quarter of 2022 relating to the reduction in force, which is expected to consist of employee severance and other restructuring related costs and expenses.”

Commerce.com, Inc. announced a restructuring with charges of approximately $4.2 million to $4.6 million affecting current workforce (approximately 13%, consisting of 9% employees and 4% contractors).

“On December 14, 2022, BigCommerce Holdings, Inc. (the “Company”) committed to a plan to reduce the Company’s current workforce by approximately 13%, consisting of 9% employees and 4% contractors. The decision was based on cost-reduction initiatives intended to reduce the Company’s cost structure and accelerate its path to profitability. The Company currently estimates that it will incur one-time cash charges of approximately $4.2 million to $4.6 million in connection with the reduction in force, primarily consisting of severance payments, employee benefits and related costs.”

Laird Superfood, Inc. announced a impairment with charges of non-cash charges related to the impairment of its right of use assets and factory equipment of up to $5.3 million in the fourth quarter of 2022, as well as rela affecting its three leaseholds in Sisters, Oregon and the sale of operations equipment and personal property in such facilities.

“On December 9, 2022 the Company signed agreements for early exit of its three leaseholds in Sisters, Oregon and the sale of operations equipment and personal property in such facilities. The Company will gain no operational benefit from the leaseholds beginning late December 2022, and will terminate the lease agreements on January 31, 2023. As such, the Company anticipates that it will incur non-cash charges related to the impairment of its right of use assets and factory equipment of up to $5.3 million in the fourth quarter of 2022, as well as related net cash payments of $0.7 million expected to be made over the next 14 months.”

Warner Bros. Discovery, Inc. announced a restructuring with charges of total pre-tax restructuring charges of $4.1 - $5.3 billion.

“The Company now expects to incur total pre-tax restructuring charges of $4.1 - $5.3 billion, which includes $2.8 - $3.5 billion of content impairment and development write-offs.”

Edgio, Inc. announced a restructuring with charges of approximately $2.6 million (approximately 95 employees, or approximately 10% of the Company’s global workforce).

“On December 13, 2022, the Board of Directors (the "Board") of Edgio, Inc. (the "Company") approved a restructuring plan (the “Restructuring Plan”) in order to reduce its operating costs as part of its transformational initiative to optimize its business model and increase efficiencies. The Restructuring Plan is anticipated to entail a reduction in force of approximately 95 employees, or approximately 10% of the Company’s global workforce, to be implemented through the second quarter of 2023 (the “Reduction in Force”). The Company estimates that Restructuring Plan charges will be approximately $2.6 million and will be recorded as restructuring expenses which consist of one-time severance charges and continuation of health benefits.”

ASSURANT, INC. announced a restructuring with charges of approximately $60 million to $65 million affecting business portfolio and global footprint.

“given its increasingly hybrid workforce. The Company expects to complete these actions in 2023. The Company expects to incur total pre-tax restructuring charges of approximately $60 million to $65 million, with approximately $51 million to $56 million to be incurred in fourth quarter 2022 and the remainder to be incurred in 2023. The total expected range includes”

Hyperfine, Inc. announced a restructuring with charges of up to $1.7 million affecting global workforce, including subsidiary Liminal Sciences, Inc. (approximately 13% of its global workforce).

“On December 6, 2022, Hyperfine, Inc. (the “Company”) committed to an organizational restructuring designed to decrease its costs and create a more streamlined organization to support its business. As a result, the Company has terminated approximately 13% of its global workforce including, among others, the employees of its subsidiary, Liminal Sciences, Inc. In connection with the restructuring, the Company currently estimates it will incur up to $1.7 million of costs, consisting primarily of cash severance costs, other severance benefits, fixed asset impairment costs and other related restructuring costs.”

Viant Technology Inc. announced a restructuring with charges of Non-recurring charges of approximately $1.2 million primarily consisting of cash severance payments, employee benefits and related costs affecting Company-wide (46 employees).

“Item 2.05 Costs Associated with Exit or Disposal Activities. On December 9 , 2022, Viant Technology Inc. (the “Company”) approved a plan to reduce the Company’s current workforce by 46 employees , representing approximately 13% of the Company’s total workforce. This decision was based on cost-reduction initiatives intended to reduce operating expenses and sharpen the Company’s focus on key growth priorities in light of the current adverse macroeconomic environment. The Company expects that the reduction in force will be substantially completed within approximately 60 days of December 9 , 2022. The Company currently estimates that it will incur non-recurring charges of approximately $1.2 million in connection with the reduction in force, primarily consisting of cash severance payments, employee benefits and related costs. The Company expects that substantially all of these charges will be incurred in the fourth quarter of 2022. Of the total charges, substantially all charges are expecte”

TechTarget Holdings Inc. announced a restructuring with charges of approximately $4.5 million to $5.0 million (approximately 60 positions, or approximately 5% of the Company's current workforce).

“On December 6, 2022, TechTarget, Inc. (the "Company") committed to a restructuring plan (the "Plan") intended to generate operational efficiencies, strengthen the Company's financial position through reducing costs, and better align the Company's operations with its current strategic objectives. The Plan involves streamlining the operations of certain business units within the Company and includes the elimination of approximately 60 positions, or approximately 5% of the Company's current workforce. The Company estimates that it will incur pre-tax restructuring and related charges to its GAAP financial results of approximately $4.5 million to $5.0 million”

KAMAN Corp announced a restructuring with charges of approximately $8 to $10 million affecting Orlando, Florida, manufacturing facility.

“Although the final cost of the Restructuring will not be known until all restructuring activities have been completed, the Company currently expects to incur approximately $8 to $10 million in total pre-tax restructuring charges, approximately $8 million of which are expected to be attributable to net cash payments relating to various personnel and”

Sensei Biotherapeutics, Inc. announced a restructuring with charges of approximately $1.0 million affecting Company (approximately 40% of its workforce).

“On December 5, 2022, the Board of Directors of Sensei Biotherapeutics, Inc. (the “Company”) approved a plan to reduce the Company’s current workforce by approximately 40% to decrease operating expenses. The Company expects the reduction in force to be substantially completed in the first quarter of 2023. As a result, the Company estimates that it will incur a one-time charge of approximately $1.0 million in connection with one-time employee termination costs, including severance and other benefits.”

Nerdy Inc. announced a restructuring with charges of $1 million to $2 million affecting Consumer and Institutional business categories (approximately 17% of the Company's total workforce).

“profitability by the end of 2023, as previously communicated. The Company currently estimates that it will incur one-time charges in the fourth quarter of 2022 of approximately $1 million to $2 million in connection with the workforce reductions, primarily for severance payments and related employee benefit costs. The Company expects that the implementation of the”

Instil Bio, Inc. announced a restructuring with charges of up to $20 million affecting ITIL-168 development program and U.S. workforce (approximately 60%).

“As part of the Plan, the Company’s ITIL-168 development program will be discontinued. In addition, as part of the Plan, the Company will reduce its US workforce by approximately 60%. This workforce reduction is expected to be substantially completed in February 2023. In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $20 million.”

Quotient Ltd announced a restructuring with charges of between $1.5 million to $2.5 million affecting transfusion diagnostics products commercialization (by approximately 100 positions).

“As indicated in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2022, filed November 14, 2022, the board of directors of the Company has approved a change in strategy in which the Company would suspend its activities focused on the commercialization of its transfusion diagnostics products and would instead focus in the near term on development and commercialization of MosaiQ products for the autoimmune and allergy clinical diagnostics markets. As a result of this shift in strategy, the Company will implement a material reduction in its workforce by approximately 100 positions. The Company estimates that it will incur aggregate pre-tax charges of between $1.5 million to $2.5 million.”

Bioventus Inc. announced a restructuring with charges of between $4 million and $5 million of pre-tax costs.

“The Company expects to incur between $4 million and $5 million of pre-tax costs, of which $3 million to $4 million is due to employee severance and benefits, and the remaining $1 million is due to third-parties and other related costs.”

BSQUARE CORP /WA announced a restructuring with charges of approximately $0.2 million to $0.3 million (approximately 20%).

“On December 5, 2022, Bsquare Corporation (“Bsquare” or the “Company”) enacted a reduction in workforce plan (the “Plan”) as part of broader efforts to align the Company’s cost base with its 2023 strategic and operating priorities. The Plan is expected to reduce the Company’s headcount by approximately 20%. The Company estimates the aggregate restructuring costs associated with the Plan to be approximately $0.2 million to $0.3 million, primarily consisting of severance payments, employee benefits and related costs.”

BuzzFeed, Inc. announced a restructuring with charges of $8 million to $12 million (approximately twelve (12) percent reduction in the current workforce).

“of providing, where required, WARN notice; and severance, including outplacement services and benefits continuation. We estimate that the foregoing charges will range between $8 million to $12 million, and we expect that the charges will be recognized primarily in the fourth quarter of 2022, with the majority of such charges anticipated to be paid by the end of”

Doma Holdings, Inc. announced a restructuring with charges of between approximately $9 million - $10 million in employment related charges affecting the Company (approximately 515 positions across the Company, or approximately 4 0% of t he Company’s current workforce).

“The Reduction Plan includes the elimination of approximately 515 positions across the Company, or approximately 4 0% of t he Company’s current workforce. As part of the Reduction Plan, the Company expects to incur between approximately $9 million - $10 million in employment related charges, including cash expenditures for employee benefits, salary continuation, severance payments, payroll taxes and related costs offset by forfeitures of bonus and stock-based compensation.”

Endo International plc announced a restructuring with charges of approximately $235 million to $250 million affecting Endo Aesthetics’ QWO product line (approximately 90 full-time positions).

“On December 6, 2022, Endo International plc (together with its direct and indirect subsidiaries, “ Endo ” or the “ Company ”) announced that it will cease the production and sale of Endo Aesthetics’ QWO ® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration. This decision is expected to result in annualized pre-tax cash savings of approximately $50 million to $60 million and a reduction to Endo’s global workforce of approximately 90 full-time positions. In connection with ceasing production and sales of QWO ® , Endo expects to incur total pre-tax restructuring charges of approximately $235 million to $250 million in the fourth quarter 2022.”

ZUORA INC announced a restructuring with charges of approximately $9.5 million (impacting 11% of our workforce).

“On November 30, 2022, Zuora committed to a workforce reduction plan, impacting 11% of our workforce, to improve operational efficiencies and operating costs and better align our workforce with current business needs, priorities, and near term growth expectations, in light of macroeconomic uncertainties. We expect to incur charges of approximately $9.5 million consisting primarily of termination benefits to the impacted employees, including severance payments and healthcare benefits.”

WM TECHNOLOGY, INC. announced a restructuring with charges of approximately $10.7 million (up to 175 employees, representing approximately 25% of the Company's total global workforce).

“On November 29, 2022 and December 1, 2022, the Board of Directors of WM Technology, Inc. (the “Company”) approved plans to reduce the Company’s current workforce by up to 175 employees, representing approximately 25% of the Company’s total global workforce. This decision was based on cost-reduction initiatives intended to reduce operating expenses and sharpen the Company’s focus on key growth priorities. The Company currently estimates that it will incur charges of approximately $10.7 million in connection with the reduction in force, primarily consisting of cash severance payments, employee benefits and related costs.”

Solid Biosciences Inc. announced a restructuring with charges of approximately $3.2 million (approximately 18%).

“On November 30, 2022, the Company’s Board of Directors (the “Board”) approved a plan to reduce the Company’s workforce by approximately 18%. These reductions are expected to be completed by the December 5, 2022. This plan is designed to streamline the Company’s operating structure. The Company expects to incur a charge in the fourth quarter of 2022 of approximately $3.2 million related to the reduction in force, consisting of severance and other employee termination benefits. The Company expects that approximately $0.4 million of this amount will be paid during in the fourth quarter of 2022 and the balance through the first quarter of 2024.”

EXAGEN INC. announced a restructuring with charges of approximately $750,000 (42 employees).

“On December 5, 2022, the Board of Directors of Exagen Inc. (the “Company”) approved a reduction in force intended to conserve the Company’s current cash resources. The Company will reduce its current workforce by 42 employees (the “Reduction in Force”). The Company estimates that it will incur aggregate pre-tax charges of approximately $750,000 in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs.”

TPI COMPOSITES, INC announced a restructuring with charges of approximately $45 to $60 million affecting Yangzhou, China manufacturing facility (approximately 18%).

“On December 2, 2022, TPI Composites, Inc. (the Company) committed to a restructuring plan in order to rebalance the organization and optimize its global manufacturing footprint. In connection with the plan, and as previously announced on November 3, 2022 in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company intends to cease production at its Yangzhou, China manufacturing facility. The Company will reduce its global headcount by approximately 18%, primarily in geographies most impacted by demand. The Company will take action under the restructuring plan beginning in December 2022. The Company currently estimates that it will recognize pre-tax charges to its 2022 financial results of approximately $45 to $60 million, consisting primarily of costs to shut down the Yangzhou manufacturing facility, severance and other one-time termination benefits, real estate-related charges, contract-related asset impairments and other costs.”

Royalty Pharma plc announced a impairment with charges of $273.6 million affecting financial royalty asset associated with gantenerumab.

“endpoint of slowing clinical decline, which led the Company to conclude its financial royalty asset is impaired. The Company expects that the non-cash impairment charge will be $273.6 million, which was the net carrying value of the asset as of September 30, 2022. No portion of the impairment charge relates to future cash expenditures. SIGNATURES Pursuant to the”

DoorDash, Inc. announced a restructuring with charges of approximately $ 85 million in restructuring charges (approximately 1,250 positions across the Company).

“On November 30, 2022, DoorDash, Inc. (the “Company” or “DoorDash”) committed to a reduction in workforce (the “Plan”) intended to better align the Company’s talent with its strategic priorities and to improve operating efficiency. The Plan includes the elimination of approximately 1,250 positions across the Company, or approximately 7% of the Company’s current employee workforce. The Company estimates that it will incur approximately $ 85 million in restructuring charges in connection with the Plan, consisting of approximately $ 68 million in cash expenditures for separation-related payments, benefits, and related taxes, and approximately $ 17 million in stock-based compensation related to equity compensation for employees who were terminated.”